Company news
Zhejiang Chengyi Pharmaceutical Co. Ltd. news in 2025
Zhejiang Chengyi Pharmaceutical Co. Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on the Acquisition of Drug Registration Certificate for Torasemide Tablets
December 9, 2025
Announcement on Progress in Providing Guarantee
December 2, 2025
Announcement on Completing Shareholding Reduction Plan for Person Acting in Concert of Controlling Shareholder and the Results of Shareholding Reduction
November 26, 2025
Indicative Announcement on Change in Equity of Controlling Shareholders and Persons Acting in Concert Reaching 1% Scale
November 14, 2025
Report for Q3 2025
October 27, 2025
Announcement on Completion of the Government’s Compensatory Recovery of Land and Associated Assets of Subsidiaries
October 13, 2025
Announcement on Shareholding Reduction Plan for Person Acting in Concert of Controlling Shareholder
September 19, 2025
Announcement on Outline of the 2025 Semi-annual Performance Briefing
September 18, 2025
Announcement on Completion of Non-trading Transfer under the 2025 Employee Stock Ownership Plan
September 17, 2025
Announcement on Resolutions of the 1st Holders' Meeting for 2025 Employee Stock Ownership Plan
September 16, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 15, 2025
Announcement on the Company's Drug Passing Consistency Evaluation of Generic Drug
September 12, 2025
Announcement on Obtainment of Drug Registration Certificate for Icosapent Ethyl Soft Capsules
September 1, 2025
Announcement on Appointment of Deputy General Manager
August 26, 2025
Announcement on Retirement and Resignation of Senior Management Member
August 18, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
August 11, 2025
Announcement on Abnormal Fluctuations in Stock Trading
August 6, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
August 4, 2025
Announcement on the Acquisition of Drug Registration Certificate for Peramivir Injection
July 31, 2025
Semi-annual Earnings Preannouncement for 2025
July 13, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 11, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 4, 2025
Announcement on Election of Employee Director for the 5th Board of Directors
May 20, 2025
Report for Q1 2025
April 29, 2025
Announcement on the Acquisition of Drug Registration Certificate for Mercaptopurine Tablets
April 14, 2025
Announcement on Obtaining Australia's TGA-GMP Certificate
January 10, 2025
Announcement on the Acquisition of Drug Registration Certificate for Calcitriol Soft Capsules
January 2, 2025